Most Read

This transaction is said to be contingent on receiving customary regulatory approvals. Theravia’s portfolio includes Siklos for sickle cell disease and Orphacol for genetic disorders affecting the liver’s

This collaboration primarily aims to concentrate on expediting production of the recessive dystrophic epidermolysis bullosa (RDEB) therapy CORDStrom. An independent technology and innovation organisation, CGT Catapult focuses on

The partnership will leverage Nona’s two heavy and two light chain (H2L2) Harbour Mice platforms to detect next-generation therapeutic candidates. The platform employs transgenic mice to produce fully

Spearheaded by Deep Track Capital, this funding round saw participation from new investors, including Catalio Capital Management, Cytokinetics, and AN Ventures, alongside contributions from current backers SV Health

This follows the company’s February announcement of a definitive merger agreement signed with BioSymetrics. This merger aims to bolster Renovaro’s data analysis and biomarker discovery capabilities, while also

France 2030 is a selective French government initiative to fast-track “breakthrough innovations”. The funding is an endorsement of 4MB, achieved through a multi-stage assessment by experts in science,

ALX2004 has been designed using the company’s topoisomerase I inhibitor payload platform to enhance anti-tumour activity and improve patient outcomes in EGFR-expressing tumours. The molecule, developed entirely within

This decision is based on the randomised MITIGATE trial data, which showed the antibody’s potential to reduce disease activity by minimising flares in individuals, upholding its established safety

This clearance comes after the company’s receipt of approval from New Zealand’s Medsafe last month for clinical trial application to commence a first-in-human study of the therapy. During